Disclosure of Payments to Healthcare Professionals
Our collaborations with healthcare professionals always aim to benefit patients, improve medical practices and patient care.
Activities can range from clinical research to exchanges on how new medicines fit into patient pathway.
We believe that a more open transparent relationship strengthens the basis for collaboration and is in the best interest of patients and all health stakeholders.
For this reason, we are committed to disclose our interactions with healthcare professionals and organizations through the Disclosure Code de l’EFPIA.
Autria
Public disclosure 2021, 2022, 2023
Bulgaria
Public disclosure 2021, 2022 , 2023
Croatia
Public disclosure 2023,
No Transfer of Value in 2021, 2022
Cyprus
Public disclosure 2021, 2022, 2023
Czech Republic
Public disclosure 2021, 2022 , 2023
Denmark
Public disclosure 2021, 2022 , 2023
Estonia
No Transfer of Value in 2021, 2022, 2023
Finland
Public disclosure 2021, 2022 , 2023
Greece
Report PFD 2021 / Report PFD 2022 / Report PFD 2023
Pierre Fabre Greek Crossborder ToVs 2021/ Pierre Fabre Corporate Greek Crossborder 2022 / Pierre Fabre Corporate Greek Crossborder 2023
Report PFMS 2021/ Report PFMS 2022/ Report PFMS 2023
Hungary
Public disclosure 2021, 2022, 2023
Lithuania
No Transfer of Value in 2021, 2022, 2023
Luxembourg
No transfer of Value in 2021,
Malta
No Transfer of Value in 2021, 2022, 2023
Norway
Public disclosure 2021, 2022 , 2023
Poland
Public disclosure HCP 2021, 2022, 2023
Public disclosure HCO 2021, 2022
No Transfer of Value in 2023
Public disclosure R&D 2021, 2022 , 2023
Romania
No Transfer of Value in 2021, 2022, 2023
Slovak republic
Public disclosure 2021, 2022 , 2023
Serbia
No Transfer of Value in 2021
Sweden
Public disclosure 2021, 2022, 2023
Switzerland
Public disclosure 2021, 2022, 2023
Ukraine
No Transfer of Value in 2021, 2022, 2023
DISCLOSURE METHODOLOGY PIERRE FABRE PHARMACEUTICALS TOV 2024
- The publication provided through this section is made in accordance with the Company Self-Certification 2024 .
-
Following European legislation on data privacy, recipients of published transfers of value have a right to access and correct personal data concerning them, which is exercisable by e-mail: transparency.compliance@pierre-fabre.com